B. Riley Comments on Immunic’s Q3 Earnings (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at B. Riley decreased their Q3 2025 EPS estimates for shares of Immunic in a research report issued to clients and investors on Monday, September 1st. B. Riley analyst W. Wood now anticipates that the company will post earnings of ($0.21) per share for the quarter, down from their previous estimate of ($0.12). B. Riley currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. B. Riley also issued estimates for Immunic’s Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.78) EPS and FY2026 earnings at ($0.36) EPS.

Several other equities analysts have also commented on IMUX. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Immunic in a research note on Friday, August 8th. William Blair reaffirmed an “outperform” rating on shares of Immunic in a research note on Friday, May 16th. Two research analysts have rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $7.50.

Immunic Price Performance

Shares of IMUX stock opened at $0.76 on Thursday. The firm has a market cap of $75.07 million, a PE ratio of -0.81 and a beta of 1.44. The company has a 50-day moving average of $0.88 and a two-hundred day moving average of $0.95. Immunic has a 1-year low of $0.56 and a 1-year high of $2.11.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02).

Institutional Investors Weigh In On Immunic

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC bought a new stake in Immunic in the 4th quarter valued at approximately $84,000. Bridgeway Capital Management LLC lifted its holdings in Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after acquiring an additional 22,200 shares during the period. Focus Partners Wealth raised its stake in shares of Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after buying an additional 23,610 shares during the period. Millennium Management LLC boosted its holdings in shares of Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after purchasing an additional 479,846 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Immunic by 90.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock valued at $205,000 after acquiring an additional 96,894 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.